Sabine Ott
Senior VP BD & Licensing
Ismaning
Summary
Business Development & Licensing professional with strong commercial, scientific, legal and financial acumen and 20+ years experience in the biotech industry, focused mainly on the development and realization of business opportunities and strategies, acquisition, negotiation, and transaction of licensing deals with big pharma & biotechs, R&D collaborations, and strategic alliances.
Proven track record at identifying and evaluating new business and licensing opportunities and partners worldwide and closing a broad range of transactions and partnering deals, such as collaboration and license agreements, IP out-licensing deals, in-licensing of technologies, and joint research collaborations as well as subcontractor agreements.
Experienced business professional with longstanding experience in gene and cell therapy (GCT), viral vector platforms and gene delivery, and molecular diagnostics and a solid background in molecular genetics and oncology. Profound strategic and operational experience, experienced in leadership of non-hierarchical structures, a high degree of personal initiative, and excellent team spirit with outstanding negotiation and communication skills.
Overview
23
23
years of professional experience
Work History
Senior Vice President Business Development & Licensing
REVVITY INC. (former SIRION Biotech GmbH - Acquired By PerkinElmer – Now Revvity Inc. In 2021)
4 2016 - Current
- Head of Business Development and Licensing department (team of 13 people, including Product Managers, Alliance Managers, and a lab in Heidelberg).
- BD with heavy focus on Licensing (out- and in-licensing) of proprietary technologies in the therapeutic / Cell & Gene Therapy space.
- Closed +40 deals with big pharma and biotechs, a number of in-licensing agreements and collaborations.
- After acquisition by PerkinElmer/Revvity, management of Revvity's entire licensing unit including a Base Editing platform owned by Revvity.
- In detail, more than 20 concluded IP license agreements (LentiBOOST lentiviral enhancer technology), four multi-million collaboration & licensing deals (e.g. Sanofi Genzyme) - AAV development for gene therapy)
- Responsible and accountable for the entire chain from lead generation to negotiation and deal transaction in close collaboration with IP and legal.
- Maintained consistent growth in revenue, contribution margin, operating profit, and EBITDA
- Identified opportunities to improve business process flows and productivity
- Developed and implemented new strategies and policies to establish long-term business objectives and provide strong and sustainable organizational leadership
Business Development and Marketing Director
GeneWake GmbH
2011.10 - 2015.12
- Overall responsibility for business and corporate development and strategic marketing of innovative diagnostics and services
- Elaboration of new business fields and further improvement of existing business models for diagnostics development, patient testing and contract research
- Set-up of a novel patient testing business unit from standard tests up to highly innovative blood-based biomarker panel tests for prostate cancer
- Evaluation of reimbursement strategies for GeneWake’s proprietary tests
- Writing of grant applications and technical reports for annual grant reports
- Set-up and implementation of clinical studies for innovative molecular diagnostics with special focus on oncology
- Close cooperation with department heads of hospitals
- Responsibility for international marketing and public relations
Managing director ForZebRA Research Association
Surgical Clinic and Polyclinic of the LMU Munich
2008.10 - 2012.01
- Management of the Bavarian Research Association ForZebRA (research for cell-based regeneration during ageing) consisting of nine academic and twelve industrial partners (e.g. Novartis and Siemens)
- Governance, controlling, development of strategic alliances and networks
- Public Relations by press releases, articles in scientific journals, newsletters, and in public journals
- Realization of trade fair participations, symposia, project meetings, and evaluations
- Representation of the research association via multiple talks and conferences.
Global Marketing Manager
MWG Biotech AG, Ebersberg
2004.02 - 2006.05
- Development of marketing concepts and sales strategies for established and new product lines
- Planning and realization of product launches
- Strategic direction of market and competitor analyses in close cooperation with MWG’s local marketing managers of the subsidiaries
- Planning and execution of mailings and e-mailings, online and print advertisements and flyers
- Organization of road shows and fairs, regular trainings of the sales team and of export managers
- Redesign of the Website and optimization of e-commerce pages.
Product Manager Genomic Diagnosis
MWG Biotech AG, Ebersberg
2001.02 - 2003.07
- Management of the new product line Genomic Diagnosis: DNA microarrays, microarray instruments, and SNP genotyping
- Conduction of market and competitor analyses and evaluation of product positioning
- Preparation of forecasts and participation in strategic marketing strategies
- Planning of marketing initiatives for the development and commercialization of MWG arrays
- Assistance in the development and implementation of product branding and marketing positioning
Education
Ph.D. - Biology - Molecular Genetics
University of Konstanz
Konstanz02.2001
Diploma - Molecular Biology
University Konstanz
Konstanz08.1998
Skills
Negotiation: Advanced Negotiator diploma Schranner Institute
Leadership & Management skills
Building of Licensing department from scratch to a >15M franchise
Business Development: huge network in the cell and gene therapy space
German: mother tongue
English: business fluent
Publications
- Jahr, S, Hentze, H., Knippers, R. et al., Cancer Research (2001); 61: 1659-1665 DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells,
- Jahr, S, Lewalter, T., Hesch, R.D., et al., Hum. Mutat. (2000); 15: 584-585 New missense mutation in the predicted selectivity filter of the HERG channel associated with familial LongQT syndrome, Lewalter Th., Englisch, S.,
- Jahr, S.et al., Z. Kardiol. (1998); 87:517-521 QT syndrome: new diagnostic possibilities.
Timeline
Business Development and Marketing Director
GeneWake GmbH
2011.10 - 2015.12
Managing director ForZebRA Research Association
Surgical Clinic and Polyclinic of the LMU Munich
2008.10 - 2012.01
Global Marketing Manager
MWG Biotech AG, Ebersberg
2004.02 - 2006.05
Product Manager Genomic Diagnosis
MWG Biotech AG, Ebersberg
2001.02 - 2003.07
Senior Vice President Business Development & Licensing
REVVITY INC. (former SIRION Biotech GmbH - Acquired By PerkinElmer – Now Revvity Inc. In 2021)
4 2016 - Current
Ph.D. - Biology - Molecular Genetics
University of Konstanz
Diploma - Molecular Biology
University Konstanz
Similar Profiles
RAMAN SINGHRAMAN SINGH
Head of Enterprise Technology & Digital Transformation at REVVITY INC, (formerly PERKINELMER)Head of Enterprise Technology & Digital Transformation at REVVITY INC, (formerly PERKINELMER)
Susan CurranSusan Curran
Senior Director, Global HR Enablement at Revvity (formerly PerkinElmer)Senior Director, Global HR Enablement at Revvity (formerly PerkinElmer)
Ramkumar KarlapudiRamkumar Karlapudi
Assistant Manager at Revvity Healthcare India Pvt LtdAssistant Manager at Revvity Healthcare India Pvt Ltd